|
|
Article: Epimmune Enters Agreement For $13.5M Stock Merger With Anosys.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Epimmune Inc.'s merger with Anosys Inc. appears to be coming to fruition by way of a stock transaction initially valued at $13.5 million.
Though officials at both companies declined to discuss the deal after entering a quiet period related to a pending financing, the merger talks go back several months. Three months ago Epimmune publicly disclosed the idea of combining its epitope technology with Anosys' exosome delivery technology to create therapeutics that activate antigen-specific immune responses - in particular, cancer vaccines. (See BioWorld Today, Feb. 14, 2003.)
But the companies' relationship runs much longer, as Epimmune ...